Clinical Trial

Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant Cyclophosphamide

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To evalute the safety and efficacy in reducing Cytokine Release Syndrome after hematopoietic stem cell transplantation by introducing immunosuppression earlier in the transplant process
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-02-11; most recent amendment 2026-04-15.
Status change: Not Yet Recruiting → Recruiting 2025-10-29
Trial Details
NCT Number NCT06828796
Lead Sponsor Northside Hospital, Inc.
Conditions Hematologic Disease and Disorders, Hematopoietic Cell Transplant
Enrollment 20 participants
Start Date 2025-07-03
Primary Completion 2027-06-30 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-16